A small number of people who are infected with HIV-1 produce very special antibodies. These antibodies do not just fight one virus strain, but neutralize almost all known virus strains. Research into developing an HIV vaccine focuses on discovering the factors responsible for the production of such antibodies.
A research team has been searching for these factors for years. Several have already been identified: For example, the virus load and the diversity of the viruses, the duration of the infection, and the ethnicity of the affected person can all influence the body's immune response. "In our new study, we were able to identify another factor: The genome of the HI virus," says the senior author.
The starting point for the researchers was the data and biobanked blood samples of around 4,500 HIV-infected people, recorded in the Swiss HIV Cohort Study and the Zurich Primary HIV Infection Study. In total the researchers found 303 potential transmission pairs - i.e. pairs of patients for whom the similarity of the viruses' genomic RNA indicated that they were probably infected with the same virus strain. "By comparing the immune response of these pairs of patients, we were able to show that the HI virus itself has an influence on the extent and specificity of the antibody reactions," explains the study's first author.
Antibodies acting against HIV bind to proteins found on the surface of the virus. These envelope proteins differ according to virus strain and subtype. The researchers therefore examined more closely a patient pair with very similar virus genomes and at the same time very strong activity of broadly neutralizing antibodies. "We discovered that there must be a special envelope protein that causes an efficient defense," explains another author.
In order to be able to develop an effective vaccine against HIV-1, it is necessary to pinpoint the envelope proteins and virus strains that lead to the formation of broadly acting antibodies. It is therefore planned to widen the search. "We have found one candidate. Based on that, we now want to begin developing an immunogen ourselves," adds the author.
http://www.media.uzh.ch/en/Press-Releases/2018/HIV-Vaccine.html
https://www.nature.com/articles/s41586-018-0517-0
Latest News
A new brain circuit in mice…
By newseditor
Posted 08 May
Mechanism of choline entry…
By newseditor
Posted 07 May
Link between UTI and breast…
By newseditor
Posted 07 May
Sleep resets brain connections
By newseditor
Posted 07 May
Interplay of various enzyme…
By newseditor
Posted 07 May
Other Top Stories
Characterizing miRNA-regulatory networks
Read more
Mechanism of FGF receptor dimerization and activation
Read more
Posttranslational modification of mitochondrial proteins
Read more
DNA looping to regulate miR-200c/141 expression involved in oxidati…
Read more
Linking nutrients and growth factors availability to ribosomal RNA…
Read more
Protocols
Single-cell adhesive profil…
By newseditor
Posted 07 May
Parasympathetic neurons der…
By newseditor
Posted 07 May
Non-invasive measurements o…
By newseditor
Posted 05 May
A validation strategy to as…
By newseditor
Posted 04 May
Generation of rat forebrain…
By newseditor
Posted 03 May
Publications
Astrocytic Slc4a4 regulates…
By newseditor
Posted 08 May
Diabetic retinopathy is a c…
By newseditor
Posted 08 May
A body-brain circuit that r…
By newseditor
Posted 07 May
Host response during unreso…
By newseditor
Posted 07 May
Sleep pressure modulates si…
By newseditor
Posted 07 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar